Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Capt Smith.. Thanks for the info
AND What a great website. We are wasting out time with NRTI. They are falling further behind with each passing day.
Something is drastically wrong with management and they are wasting shareholder value.
TRTC is offering their IVXX products in over 8 dispensaries in California, and has issued PRs each time they add one. Why isn't NRTI piggy backing our so called "Partner" and offering Nulief there too?
At this share price it doesn't pay to sell. The loss is too big. But I certainly wont be throwing anymore good money at this.
For something with so much promise and verifiable need,they sure have screwed up the roll out.
IsoRay's Cesium-131 Cancer Treatment Takes Center Stage at Weill Cornell's International Symposium "Advances in Brachytherapy"
Successful Cesium-131 Cancer Treatment Results, Methods and Patient Selection Criteria Were Presented in a Peer to Peer Forum of Leading Medical Professionals
Marketwired IsoRay, Inc.
May 11, 2015 8:30 AM
RICHLAND, WA--(Marketwired - May 11, 2015) - IsoRay, Inc. (NYSE MKT: ISR), a medical technology company and innovator in brachytherapy and medical isotope applications, today announced that a number of industry leaders discussed the successes achieved by their patients in a variety of body sites being treated with IsoRay's Cesium-131 internal radiation (brachytherapy) cancer seeds at the "Advances in Brachytherapy" symposium, held at Weill Cornell on Friday and Saturday.
IsoRay Chairman and CEO Dwight Babcock commented, "We are so very pleased to have studies presented reporting successes in peer to peer presentations. Data from ongoing studies continues to be gathered and when it matures the expectation is that it will be peer reviewed and published. We are now hearing from more institutions based on our new recently released peer reviewed publications. Medical professionals rely on these publications to further their practice and learn about new leading edge products."
NOTES FROM THE FIELD AT THE SYMPOSIUM
1.) LDR Brachytherapy: MD Anderson Experience - Steve Frank, M.D.
Dr. Frank discussed the ongoing prostate cancer trial at MD Anderson Cancer Center in Houston, including the use of Cesium-131 as treatment. He also discussed the emerging use of magnetic resonance (MR) imaging in determining radiation doses delivered following prostate brachytherapy. Cesium-131 was the first isotope chosen to be used in conjunction with the MRI spacer.
2.) Role of Brachytherapy in Recurrent H&N Cancers - Bhupesh Parashar, M.D.
Dr. Parashar discussed the option of Cesium-131 brachytherapy as part of the management of recurrent head and neck cancers. Details on this study were recently presented at the 97th Annual Meeting of the American Radium Society.
3.) Resection with intraoperative Cs-131 Brachytherapy in Newly Diagnosed Brain Metastases and Recurrent GBM: Techniques and Outcomes - Theodore Schwartz, M.D. and A. Gabriella Wernicke, M.D.
Drs. Schwartz and Wernicke described their study, published recently in the Journal of Neurosurgery, where very high rates of control have been seen in the treatment of metastatic brain cancer. In particular they noted the benefit of Cesium-131 treatment in tandem with surgery over waiting weeks or months to perform other types of radiation treatment. Their group continues to add patients to their existing study and they are planning a trial to compare Cesium-131 treatment to other radiation treatments in the treatment of brain metastases.
4.) Impact of Brachytherapy on Local Recurrence Rates after Sublobar Resection in Early Stage Non-Small Cell Lung Cancer - Bhupesh Parashar, M.D.
Dr. Parashar discussed the role of Cesium-131 brachytherapy in addition to lung sparing wedge resection surgery for patients with operable lung cancers. Although there is some discussion ongoing regarding the use of brachytherapy in these cases, Dr. Parashar stated that he continues to see the value of Cesium-131 brachytherapy for appropriately selected patients.
IsoRay Chairman and CEO Dwight Babcock noted, "Cesium-131 continues to impress medical professionals as reported successes are showing positive results in treating some of the toughest cancer cases. Many of our cases are brought by physicians seeking solutions where first line treatments have failed. Following Cesium-131 treatment, patients are having better outcomes with improved quality of life. Therapy with Cs-131 is successfully treating patients who failed conventional therapies and we believe that it could help many other patients. We are extremely excited to see that Cesium-131 isotope seeds continue to perform so well against aggressive cancers throughout the body. We remain committed to helping patients afflicted with these horrible cancers and enhancing their quality of life."
IsoRay's various products, including Cesium-131 seeds, sutured seeds, stranded mesh and the GliaSite® radiation therapy system, give physicians the ability to directly place a specified dosage of radiation in areas where cancer is most likely to remain after completion of a tumor removal or by placing seeds within the prostate. The ability to precisely place a specified dose of radiation means there is less likelihood for damage to occur to healthy surrounding tissue compared to other alternative treatments. IsoRay's cancer fighting products diminish the ability of the tumor to recur, resulting in important benefits for patients in longevity as well as quality of life.
About IsoRay
IsoRay, Inc., through its subsidiary, IsoRay Medical, Inc. is the sole producer of Cesium-131 brachytherapy seeds, which are expanding brachytherapy options throughout the body. Learn more about this innovative Richland, Washington company and explore the many benefits and uses of GliaSite® and Cesium-131 by visiting www.isoray.com. Join us on Facebook/Isoray. Follow us on Twitter @Isoray.
Safe Harbor Statement
Statements in this news release about IsoRay's future expectations, including: the advantages of our products and their delivery systems, whether IsoRay will be able to continue to expand its base beyond prostate cancer, whether the use of our products will increase or continue, whether we will continue to receive support from industry leaders, whether awareness and adoption of our products in the medical community will continue or increase, whether ultimate study results will be favorable or will ultimately be peer reviewed and published, whether future studies of treatment of various cancers using our products will have favorable results, and all other statements in this release, other than historical facts, are "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995 ("PSLRA"). This statement is included for the express purpose of availing IsoRay, Inc. of the protections of the safe harbor provisions of the PSLRA. It is important to note that actual results and ultimate corporate actions could differ materially from those in such forward-looking statements based on such factors as physician acceptance, training and use of our products, our ability to successfully manufacture, market and sell our products, our ability to manufacture our products in sufficient quantities to meet demand within required delivery time periods while meeting our quality control standards, our ability to enforce our intellectual property rights, whether additional studies are released and support the conclusions of past studies, whether ongoing patient results with our products are favorable and in line with the conclusions of clinical studies and initial patient results, patient results achieved when our products are used for the treatment of cancers and malignant diseases beyond prostate, successful completion of future research and development activities, whether we, our distributors and our customers will successfully obtain and maintain all required regulatory approvals and licenses to market, sell and use our products in its various forms, continued compliance with ISO standards as audited by BSI, the success of our sales and marketing efforts, changes in reimbursement rates, changes in laws and regulations applicable to our products, and other risks detailed from time to time in IsoRay's reports filed with the SEC.
Contact:
IsoRay Medical
Info@Isoray.com
(509) 375-1202
Or
Worldwide Financial
Info@wwfinancial.com
(954) 360-9998
CN.... With the elimination of MSE
will the company have to write off the loss in first qtr or 2nd, and how many millions of dollars will that be?
Can revenues off set that loss?
Thomas Jefferson University Launches Major Head and Neck Cancer Study Utilizing Cesium-131 Where Current Standard of Care Treatments Have Failed
Successful Cesium-131 Cancer Treatment Results, as Reported by Other Institutions, Are Driving New Institutions to Offer Cesium-131 Therapy
Marketwired IsoRay, Inc.
RICHLAND, WA--(Marketwired - May 7, 2015) - IsoRay, Inc. (NYSE MKT: ISR), a medical technology company and innovator in brachytherapy and medical isotope applications, today announced the start of a new study of head and neck cancer patients being treated with IsoRay's Cesium-131 internal radiation (brachytherapy) cancer seeds. The study is being conducted at Thomas Jefferson University, a leading, highly recognized national institution in the cancer therapy field.
IsoRay Chairman and CEO Dwight Babcock, commented, "Cancers that recur in the head and neck pose major problems. They have shown a resistance to the standard therapies of surgery and conventional radiation, leading to significant and life-altering complications."
Thomas Jefferson University has combined the efforts of its Otolaryngology/Head and Neck Surgery and Radiation Oncology departments to provide a new treatment option for patients with recurrence of head and neck cancers. Following surgical resection of the tumor, this targeted therapy allows for localized Cesium-131 (Cs-131) radioactive seeds placed directly in the tumor bed. (IRB approved study 15D-067). "Cs-131 is a favorable isotope for use across a wide range of tumors and its dose distribution properties facilitate easy calculation and use in the clinic and a decrease in the exposure to radiation oncologists, staff and patient families," says Voichita Bar Ad, MD, the lead radiation oncologist of this program. While Cs-131 seeds have been used in a number of other disease sites, this study of application in the head and neck region places Jefferson as one of the pioneers of this novel therapy. These low energy radiation sources with a short half-life allow patients to be discharged following surgical recovery without need for long term radiation precautions. "This study may afford us the opportunity to improve the poor cure rate of patients that develop recurrent head and neck cancer," says Adam Luginbuhl, MD, one of the lead investigators of the study.
IsoRay Chairman and CEO Dwight Babcock noted, "Cesium-131 continues to impress medical professionals as reported successes are showing positive results in treating some of the toughest cancer cases. Many of our cases are brought by physicians seeking solutions where first line treatments have failed. Following Cesium-131 treatment, patients are having better outcomes with improved quality of life. Therapy with Cs-131 is successfully treating patients who failed conventional therapies and we believe that it could help many other patients. We are extremely excited to see that Cesium-131 isotope seeds continue to perform so well against aggressive cancers throughout the body. We remain committed to helping patients afflicted with these horrible cancers and enhancing their quality of life."
IsoRay's various products, including Cesium-131 seeds, sutured seeds, stranded mesh and the GliaSite® radiation therapy system, give physicians the ability to directly place a specified dosage of radiation in areas where cancer is most likely to remain after completion of a tumor removal or by placing seeds within the prostate. The ability to precisely place a specified dose of radiation means there is less likelihood for damage to occur to healthy surrounding tissue compared to other alternative treatments. IsoRay's cancer fighting products diminish the ability of the tumor to recur, resulting in important benefits for patients in longevity as well as quality of life.
About IsoRay
IsoRay, Inc., through its subsidiary IsoRay Medical, Inc., is the sole producer of Cesium-131 brachytherapy seeds, which are expanding brachytherapy options throughout the body. Learn more about this innovative Richland, Washington company and explore the many benefits and uses of GliaSite® and Cesium-131 by visiting www.isoray.com. Join us on Facebook/Isoray. Follow us on Twitter @Isoray.
Safe Harbor Statement
Statements in this news release about IsoRay's future expectations, including: the advantages of our products and their delivery systems, whether IsoRay will be able to continue to expand its base beyond prostate cancer, whether sales of our products will continue at historic levels or increase, whether the use of our products will increase or continue, whether we will continue to receive support from industry leaders, whether awareness of our products in the medical community will continue or increase, whether ultimate study results will be favorable, whether future studies of treatment of various cancers using our products will have favorable results, and all other statements in this release, other than historical facts, are "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995 ("PSLRA"). This statement is included for the express purpose of availing IsoRay, Inc. of the protections of the safe harbor provisions of the PSLRA. It is important to note that actual results and ultimate corporate actions could differ materially from those in such forward-looking statements based on such factors as physician acceptance, training and use of our products, our ability to successfully manufacture, market and sell our products, our ability to manufacture our products in sufficient quantities to meet demand within required delivery time periods while meeting our quality control standards, our ability to enforce our intellectual property rights, whether additional studies are released and support the conclusions of past studies, whether ongoing patient results with our products are favorable and in line with the conclusions of clinical studies and initial patient results, patient results achieved when our products are used for the treatment of cancers and malignant diseases beyond prostate, successful completion of future research and development activities, whether we, our distributors and our customers will successfully obtain and maintain all required regulatory approvals and licenses to market, sell and use our products in its various forms, continued compliance with ISO standards as audited by BSI, the success of our sales and marketing efforts, changes in reimbursement rates, changes in laws and regulations applicable to our products, and other risks detailed from time to time in IsoRay's reports filed with the SEC.
Contact:
IsoRay Medical
Info@Isoray.com
(509) 375-1202
Or
Worldwide Financial
Info@wwfinancial.com
(954) 360-9998
zekester GREAT article
Great article. Too bad the company doesn't see fit to advise the public that it is out there.
Great find and thanks for posting it.
ISR
Thanks for the chart..
Nice price increase and volume today.
Brooksda...
I appreciate your enthusiasm but have a couple of questions based on your comment: Quote "I just started looking into this treatment. ADMD is set up to really bank if given US approval."
When the FDA approval comes through, how soon before the device will actually be utilized by the medical community?
Does ADMD have a sales force? How many?
Are doctors aware of their product and will they immediately switch over from the devices they use which are manufactured by CR Bard, Theragenics and Isoray? Is there a track record for Advanced Medical's device? Are there any clinical trials with successful evidence?
This device will be a life saver, no doubt, but it is not going to be an overnight success. We are looking at a long haul.
Just my opinion and yes I am a shareholder.
It's not the article
It's the content of the article...
two factual presentations taking place next week at different venues.
Let's see what happens then.
Positive SA article ....
hope this link works
Read the full article now »
If not,here is the opening info
Todd Cox
IsoRay's Cesium-131 Long Awaited Lung Study Results Appear To Be Coming May 8th
Apr. 29, 2015 12:28 PM ET | | About: IsoRay, Inc. (ISR)
Disclosure: The author is long ISR. (More...)
Summary
Huge catalyst upcoming for IsoRay.
IsoRay has a technological monopoly in the cancer therapy market.
Independent clinical trials show incredible results using Cesium-131.
IsoRay is financially healthy.
Alliqua BioMedical, Inc. Announces Pricing of Public Offering of Common Stock
8:40 am ET April 29, 2015 (Globe Newswire)
Alliqua BioMedical, Inc. (Nasdaq:ALQA) ("Alliqua" or "the Company"), a provider of advanced wound care products, today announced the pricing of an underwritten public offering of 6,593,407 shares of its common stock at a price to the public of $4.55 per share. The offering is expected to close on or about May 4, 2015, subject to customary closing conditions. Alliqua has granted the underwriters a 30-day option to purchase up to 989,011 additional shares of common stock to cover overallotments, if any.
Cowen and Company, LLC and RBC Capital Markets, LLC are acting as the joint book-running managers for the offering, and Craig-Hallum Capital Group LLC is acting as co-manager.
The Company intends to use the net proceeds from this offering to fund the commercial expansion of its marketed products, to pursue additional product platforms, and for working capital and general corporate purposes.
A shelf registration statement on Form S-3 relating to the public offering of the shares of common stock described above was filed with the Securities and Exchange Commission ("SEC") and was declared effective on September 25, 2014. A preliminary prospectus supplement relating to the offering was filed with the SEC on April 28, 2015 and is available on the SEC's website located at http://www.sec.gov. Copies of the final prospectus supplement and the accompanying prospectus relating to the offering may be obtained, when available, from Cowen and Company, LLC, c/o Broadridge Financial Services, 1155 Long Island Avenue, Edgewood, NY, 11717, Attn: Prospectus Department, or by calling (631) 274-2806; or from RBC Capital Markets, Attention: Prospectus Department, Three World Financial Center, 200 Vesey Street 8th Floor, New York, NY 10281, or by phone at (877) 822-4089 or by emailing equityprospectus@rbccm.com.
This press release shall not constitute an offer to sell or the solicitation of an offer to buy, nor shall there be any sale of these securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction.
About Alliqua BioMedical, Inc.
Alliqua is a provider of advanced wound care solutions. Through its sales and distribution network, together with its proprietary products, Alliqua provides a suite of technological solutions to enhance the wound care practitioner's ability to deal with the challenges of healing both chronic and acute wounds.
Alliqua currently markets its line of hydrogel products for wound care under the SilverSeal(R) and Hydress(R) brands, as well as the Sorbion sachet S(R) and Sorbion sana(R) wound care products, and its TheraBond 3D(R) advanced dressing which incorporates the TheraBond 3D(R) Antimicrobial Barrier Systems technology. It also markets the advanced wound care product Biovance(R), as part of its licensing agreement with Celgene Cellular Therapeutics.
In addition, Alliqua can provide a custom manufacturing solution to partners in the medical device and cosmetics industry, utilizing its proprietary hydrogel technology. Alliqua's electron beam production process, located at its 16,500 square foot Good Manufacturing Practice (GMP) manufacturing facility in Langhorne, PA, allows Alliqua to develop and custom manufacture a wide variety of hydrogels. Alliqua's hydrogels can be customized for various transdermal applications to address market opportunities in the treatment of wounds as well as the delivery of numerous drugs or other agents for pharmaceutical and cosmetic industries.
Legal Notice Regarding Forward-Looking Statements:
This release contains forward-looking statements. Forward-looking statements are generally identifiable by the use of words like "may," "will," "should," "could," "expect," "anticipate," "estimate," "believe," "intend," or "project" or the negative of these words or other variations on these words or comparable terminology. Such statements are based on management's good faith expectations and are subject to numerous factors, risks and uncertainties that may cause actual results, the outcome of events, timing and performance to differ materially from those expressed or implied by such statements. These factors, risks and uncertainties include, but are not limited to, failure to consummate or delay in consummating the Celleration acquisition; the adequacy of the Company's liquidity to pursue its complete business objectives; inadequate capital; the Company's ability to obtain reimbursement from third-party payers for its products; loss or retirement of key executives; adverse economic conditions or intense competition; loss of a key customer or supplier; entry of new competitors and products; adverse federal, state and local government regulation; technological obsolescence of the Company's products; technical problems with the Company's research and products; the Company's ability to expand its business through strategic acquisitions; the Company's ability to integrate acquisitions and related businesses; price increases for supplies and components; and the inability to carry out research, development and commercialization plans. In addition, other factors that could cause actual results to differ materially are discussed in our Annual Report on Form 10-K filed with the SEC on February 24, 2015, our most recent Form 10-Q filings with the SEC and the preliminary prospectus filed with the SEC on April 28, 2015 in connection with the public offering. Investors and security holders are urged to read these documents free of charge on the SEC's web site at http://www.sec.gov. After the date of this press release, we do not intend to update any of the forward-looking statements to conform those statements to actual results or to changes in the Company's expectations, except as required by law.
CONTACT: Investor Relations:
Westwicke Partners on behalf of Alliqua BioMedical, Inc.
Mike Piccinino, CFA +1-443-213-0500
AlliquaBiomedical@westwicke.com
CN... Thanks...
You have posted that before and if you know the answer why don't they?
Accordingly they are in full compliance but are pretending (or don't know) not to know.
But my money is on you, that if you know, then you imparted that to them.
Thanks for all you do.
Blum Dispensary
in Oakland is about 400 miles from Anaheim or 4 hours +/- hours depending on traffic
Dennis...Thanks for reporting back to the board, BUT
Based on your first question, I don't see the answer.
Your comments were: My first question was about the "legality of Nulief in all 50 states". Mr. Kras replied that "this is a grey area... we do everything legally... other companies cut corners... we have a superior formula in Nulief".
So it's a grey area and they do everything legally. GREAT. But is the product legal or not in any states? I would think he needs to concentrate on those states and let the others fall into place.
Why did he say it is a "grey area"?
Thanks for your efforts. I have emailed them 5 times and have not received any responses. So I appreciate the information you shared.
It's nice to have a superior formula, but they need a place to sell it and let people know more.
Thanks Bud..
This is what I found at their website...
Home
Our Menu
Clones
The Hash Bar
News
Contact Us
Search results for: Nulief
Sorry, no posts matched your criteria.
Great work, as always CN
CN..Regarding the video
Thanks for pointing that out. I missed seeing it, but after reading the PR again, I see where,IMO it was hidden like an after thought.
By the way, have yu checked facebook or twitter to see if there is any announcement about the availability of Nulief/ I am not a member of either.
Too bad you didnt apply for the social media position. You would already have the wires burning up and we would be out of product.
Thanks again.
CN .. Thanks for pushing management in the right direction.
Blum has only one outlet. I guess its a start!
I wonder when the video will be available for viewing and PR'd.
Thanks for all your efforts.
Is it available on line too?
Alliqua BioMedical, Inc. Announces Preliminary First Quarter 2015 Revenue Results & Updates Fiscal Year 2015 Revenue Guidance
First Fiscal Quarter With Revenue in Excess of $2 Million
LANGHORNE, Pa., April 23, 2015 (GLOBE NEWSWIRE) -- Alliqua BioMedical, Inc. (Nasdaq:ALQA) ("Alliqua" or "the Company"), a provider of advanced wound care products, today announced preliminary financial results for the first quarter ended March 31, 2015.
Q1 Highlights:
Total revenue increased approximately 258% year-over-year to approximately $2.1 million. Organic revenue growth was approximately 170% year-over-year.
Proprietary products revenue increased approximately 1,215% year-over-year to approximately $1.5 million. Organic proprietary product revenue growth was approximately 748% year-over-year.
The Company is updating its revenue guidance for the fiscal year 2015 period. The Company now expects total revenue in a range of $16.3 million to $18.8 million, compared to a previous expectation of revenue in a range of $15.5 million to $18 million.
The updated guidance reflects the expected incremental contributions from the acquisition of Celleration, Inc. ("Celleration"), based on a new expected closing date of May 29, 2015, compared to the prior expected closing date of June 30, 2015. Accordingly, the Company expects its revenue attributable to the Celleration business to be in the range of approximately $5.3 million to $5.8 million, compared to the Company's previous expectation of revenue attributable to the Celleration business in a range of $4.5 million to $5.0 million.
"We are pleased with our first quarter revenue performance and feel that we are off to a great start to fiscal year 2015," said David Johnson, Chief Executive Officer of Alliqua. "Our preliminary first fiscal quarter revenue result in excess of $2 million was driven by solid contributions from our proprietary products segment, particularly our Sorbion franchise, and strong growth in our contract manufacturing business."
"Our recently announced agreement to acquire Celleration is proceeding ahead of plan, and we now expect to close on May 29th. We continue to remain focused on obtaining Medicare Administrative Contractor (MAC) coverage for our Biovance Human Amniotic Membrane Allograft, and we were pleased to announce that we added our first MAC, Novitas, on April 10th. In light of our accomplishments so far this year, I am proud of our significant progress, and look forward to the future for Alliqua, as we continue to execute on our strategic growth plan, expand our addressable market and drive adoption of our innovative technologies in the advanced wound care market."
About Alliqua BioMedical, Inc.
Alliqua is a provider of advanced wound care solutions. Through its sales and distribution network, together with its proprietary products, Alliqua provides a suite of technological solutions to enhance the wound care practitioner's ability to deal with the challenges of healing both chronic and acute wounds.
Alliqua currently markets its line of hydrogel products for wound care under the SilverSeal® and Hydress® brands, as well as the Sorbion sachet S® and Sorbion sana® wound care products, and its TheraBond 3D® advanced dressing which incorporates the TheraBond 3D® Antimicrobial Barrier Systems technology. It also markets the advanced wound care product Biovance®, as part of its licensing agreement with Celgene Cellular Therapeutics.
In addition, Alliqua can provide a custom manufacturing solution to partners in the medical device and cosmetics industry, utilizing its proprietary hydrogel technology. Alliqua's electron beam production process, located at its 16,500 square foot Good Manufacturing Practice (GMP) manufacturing facility in Langhorne, PA, allows Alliqua to develop and custom manufacture a wide variety of hydrogels. Alliqua's hydrogels can be customized for various transdermal applications to address market opportunities in the treatment of wounds as well as the delivery of numerous drugs or other agents for pharmaceutical and cosmetic industries.
For additional information, please visit http://www.alliqua.com. To receive future press releases via email, please visit http://ir.stockpr.com/alliqua/email-alerts.
Legal Notice Regarding Forward-Looking Statements:
This release contains forward-looking statements. Forward-looking statements are generally identifiable by the use of words like "may," "will," "should," "could," "expect," "anticipate," "estimate," "believe," "intend," or "project" or the negative of these words or other variations on these words or comparable terminology. Such statements are based on management's good faith expectations and are subject to numerous factors, risks and uncertainties that may cause actual results, the outcome of events, timing and performance to differ materially from those expressed or implied by such statements. These factors, risks and uncertainties include, but are not limited to, failure to consummate or delay in consummating the Celleration acquisition; the adequacy of the Company's liquidity to pursue its complete business objectives; inadequate capital; the Company's ability to obtain reimbursement from third-party payers for its products; loss or retirement of key executives; adverse economic conditions or intense competition; loss of a key customer or supplier; entry of new competitors and products; adverse federal, state and local government regulation; technological obsolescence of the Company's products; technical problems with the Company's research and products; the Company's ability to expand its business through strategic acquisitions; the Company's ability to integrate acquisitions and related businesses; price increases for supplies and components; and the inability to carry out research, development and commercialization plans. In addition, other factors that could cause actual results to differ materially are discussed in our Annual Report on Form 10-K filed with the SEC on February 24, 2015, and our most recent Form 10-Q filings with the SEC. Investors and security holders are urged to read these documents free of charge on the SEC's web site at http://www.sec.gov. After the date of this press release, we do not intend to update any of the forward-looking statements to conform those statements to actual results or to changes in the Company's expectations, except as required by law.
CONTACT: Investor Relations:
Westwicke Partners on behalf of Alliqua BioMedical, Inc.
Mike Piccinino, CFA +1-443-213-0500
AlliquaBiomedical@westwicke.com
Alliqua, Inc. logo
Source: Alliqua BioMedical, Inc.
Released April 23, 2015
ISR exhibiting and presenting at AANS Annual Scientific Meeting
The American Association of Neurological Surgeons (AANS) Annual Scientific Meeting is the world's premier neurosurgical event. We are anticipating over 3,000 neurosurgeons and other healthcare professionals. This year's program will include an international symposium, superb invited speakers, practical clinics, breakfast seminars and 3D Sessions in addition to oral paper presentations and electronic poster presentations.
What are the exhibition dates and times for the 2015 AANS Annual Scientific Meeting?
Monday, May 4 9:00 a.m. - 4 p.m.
Tuesday, May 5 9:00 a.m. - 4 p.m.
Wednesday, May 6 9:00 a.m. - 2:15 p.m.
Where are the exhibits located?
The exhibits are located in the Walter E. Washington Convention Center.
What is the address of the convention center?
Walter E. Washington Convention Center
801 Mt. Vernon Place, NW
Washington, D.C.
It's about time a real professional organization is retained to promote our company..
A perfect example:
About RedChip
RedChip Companies, an Inc. 5000 company, is an international small-cap research, investor relations, and media company headquartered in Orlando, Florida; with affiliate offices in San Francisco, Pittsburgh, and Seoul. RedChip delivers concrete, measurable results for its clients through its extensive global network of small-cap institutional and retail investors. RedChip has developed the most comprehensive platform of products and services for small-cap companies, which includes: Research Reports, Retail and Institutional Marketing, Institutional and Retail Road Shows, Global Online CEO Conferences, an International TV show, The RedChip Small-Cap Reportâ„¢, featuring small-cap companies, airing weekly on Fox Business, Bloomberg Europe, and Bloomberg Asia in over 200 million homes, Shareholder Intelligence, Strategic Marketing, Crisis Management, Social Media, Blogging Services, and Webcasts. To learn more about RedChip's products and services, please visit: http://www.redchip.com/our_services
I emailed them twice more..NO response at all.
Very disappointing.
Sent an email expressing my displeasure and asking for immediate action!
Looks like they were options grants
along with two others
Table II - Derivative Securities Beneficially Owned ( e.g. , puts, calls, warrants, options, convertible securities)
1. Title of Derivate Security
(Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Trans. Date 3A. Deemed Execution Date, if any 4. Trans. Code
(Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D)
(Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date 7. Title and Amount of Securities Underlying Derivative Security
(Instr. 3 and 4) 8. Price of Derivative Security
(Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form of Derivative Security: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V (A) (D) Date Exercisable Expiration Date Title Amount or Number of Shares
Options (Right to Buy) $0.14 4/10/2015 A 1000000 (1) 4/9/2025 Common stock 1000000 $0 1000000 D
Alliqua BioMedical, Inc. Receives Coverage From Medicare Administrative Contractor (MAC) for Biovance(R)
LANGHORNE, Pa., April 16, 2015 (GLOBE NEWSWIRE) -- Alliqua BioMedical, Inc. (Nasdaq:ALQA) ("Alliqua" or "the Company"), a provider of advanced wound care products, today announced that Alliqua's Biovance® Human Amniotic Membrane Allograft, has received coverage from Novitas Solutions, Inc. ("Novitas"), a Medicare Administrative Contractor, or "MAC".
Novitas is one of eight MACs that are responsible for processing Medicare claims in one or more of twelve geographic areas, or "jurisdictions," in the United States. In addition to processing claims, each MAC is also responsible for issuing local coverage determinations ("LCDs") that specify which health care products and services are reimbursable through the Medicare Fee-for-Service program in the regions under its jurisdiction.
On Friday, April 10th, Novitas Solutions, Inc. published a local coverage determination titled "Application of Bioengineered Skin Substitutes to Lower Extremity Chronic Non-Healing Wounds (L27549),"1 which included Alliqua's Biovance Human Amniotic Membrane Allograft. Novitas has jurisdiction in two geographic areas, including eleven states and the District of Columbia. This LCD was effective for services performed on or after April 9, 2015.
"We are extremely pleased with the recent announcement from Novitas, the first MAC to include our Biovance Human Amniotic Membrane Allograft in a local coverage determination," said Brad Barton, Chief Operating Officer of Alliqua. "Novitas is responsible for approximately 11.3 million Medicare beneficiaries within its jurisdictions. This local coverage determination from Novitas allows physicians and wound care practitioners to offer Biovance to their Medicare beneficiaries, and we view this announcement as another important step towards our goal of obtaining comprehensive reimbursement coverage in the outpatient market setting."
Background:
In November 2013, Alliqua entered into an exclusive licensing agreement with Celgene Cellular Therapeutics ("CCT"), a subsidiary of Celgene Corporation, whereby Alliqua received the right to develop and market Biovance. Under the licensing agreement, the field of use is for the management of non-infected partial- and full-thickness wounds, including chronic and acute wounds such as diabetic ulcers, pressure ulcers, venous ulcers, chronic vascular ulcers, tunnel/undermined wounds, surgical wounds (donor sites/grafts, dehiscence), trauma wounds (abrasions, lacerations, second degree burns, and skin tears), and draining wounds.
On October 6, 2014, it was announced that the field of use for Biovance was expanded to include podiatric and orthopedic applications including sports medicine-related conditions pertaining to use during the repair of tendon, nerve and bone in the foot and ankle, as well as other surgical procedures in these specialty areas.
On November 3, 2014, Alliqua announced that Biovance was assigned a new Level II Healthcare Common Procedure Coding System (HCPCS) product reimbursement Q code (Q4154) by the Centers for Medicare and Medicaid Services. Biovance's Q code assignment pertains to the Level II HCPCS coding system, and is used to identify products, supplies and services employed outside of a physician's office, which are not included in the Level I HCPCS coding system. The new reimbursement code became effective on January 1, 2015.
1 http://www.novitas-solutions.com/LCDSearchResults/faces/spaces/search/page/lcd.jspx?Jurisdiction=JH&medicareType=Part+B&_afrWindowMode=0&lcdID=L27549&_afrLoop=402100223958000&State=Texas&_adf.ctrl-state=ji4bvhdoa_4
About Alliqua BioMedical, Inc.
Alliqua is a provider of advanced wound care solutions. Through its sales and distribution network, together with its proprietary products, Alliqua provides a suite of technological solutions to enhance the wound care practitioner's ability to deal with the challenges of healing both chronic and acute wounds.
Alliqua currently markets its line of hydrogel products for wound care under the SilverSeal® and Hydress® brands, as well as the Sorbion sachet S® and Sorbion sana® wound care products, and its TheraBond 3D® advanced dressing which incorporates the TheraBond 3D® Antimicrobial Barrier Systems technology. It also markets the advanced wound care product Biovance®, as part of its licensing agreement with Celgene Cellular Therapeutics.
In addition, Alliqua can provide a custom manufacturing solution to partners in the medical device and cosmetics industry, utilizing its proprietary hydrogel technology. Alliqua's electron beam production process, located at its 16,000 square foot GMP manufacturing facility in Langhorne, PA, allows Alliqua to develop and custom manufacture a wide variety of hydrogels. Alliqua's hydrogels can be customized for various transdermal applications to address market opportunities in the treatment of wounds as well as the delivery of numerous drugs or other agents for pharmaceutical and cosmetic industries.
For additional information, please visit http://www.alliqua.com. To receive future press releases via email, please visit http://ir.stockpr.com/alliqua/email-alerts.
Legal Notice Regarding Forward-Looking Statements:
This release contains forward-looking statements. Forward-looking statements are generally identifiable by the use of words like "may," "will," "should," "could," "expect," "anticipate," "estimate," "believe," "intend," or "project" or the negative of these words or other variations on these words or comparable terminology. The reader is cautioned not to put undue reliance on these forward-looking statements, as these statements are subject to numerous factors and uncertainties outside of our control that can make such statements untrue, including, but not limited to, the adequacy of the Company's liquidity to pursue its complete business objectives; inadequate capital; the Company's ability to obtain reimbursement from third party payers for its products; loss or retirement of key executives; adverse economic conditions or intense competition; loss of a key customer or supplier; entry of new competitors and products; adverse federal, state and local government regulation; technological obsolescence of the Company's products; technical problems with the Company's research and products; the Company's ability to expand its business through strategic acquisitions; the Company's ability to integrate acquisitions and related businesses; price increases for supplies and components; and the inability to carry out research, development and commercialization plans. In addition, other factors that could cause actual results to differ materially are discussed in our Annual Report on Form 10-K filed with the SEC on February 24, 2015, and our most recent Form 10-Q filings with the SEC. Investors and security holders are urged to read these documents free of charge on the SEC's web site at http://www.sec.gov. We undertake no obligation to publicly update or revise our forward-looking statements as a result of new information, future events or otherwise.
CONTACT: Investor Relations:
Westwicke Partners on behalf of Alliqua Biomedical, Inc.
Mike Piccinino, CFA +1-443-213-0500
AlliquaBiomedical@westwicke.com
Chardan Capital Initiates Coverage with $8 PT 4/10/15
Cant get the link to copy and paste.
Maybe MSE should be rebranded...
Maybe the MSE line should be rebranded as Bikini Ready
Lewis Drugs...46 Stores
Convenient locations in South Dakota, Minnesota and Iowa. Find a store near you.
IA
Lewis Family Drug: Ida Grove - Ida Grove, IA
Lewis Family Drug: Kingsley - Kingsley, IA
Lewis Family Drug: Rock Rapids - Rock Rapids, IA
Long Term Care: Rock Rapids - Rock Rapids, IA
Lewis Family Drug: Rock Valley - Rock Valley, IA
Lewis Family Drug: Sheldon - Sheldon, IA
Lewis Family Drug: Sibley - Sibley, IA
Lewis Family Drug: Sioux Center - Sioux Center, IA
Lewis Family Drug: Spirit Lake - Spirit Lake, IA
MN
Lewis Family Drug: Appleton - Appleton, MN
Lewis Family Drug: Benson - Benson, MN
Lewis Family Drug: Browns Valley - Browns Valley, MN
Lewis Family Drug: Graceville - Graceville, MN
Lewis Family Drug: Jackson - Jackson, MN
Lewis Family Drug: Lakefield - Lakefield, MN
Lewis Family Drug: Luverne - Luverne, MN
Lewis Family Drug: Ortonville - Ortonville, MN
Lewis Family Drug: Windom - Windom, MN
SD
Lewis Family Drug: Beresford - Beresford, SD
Lewis Express: Brandon - Brandon, SD
Lewis Drug: Brookings - Brookings, SD
Lewis Family Drug: Canton - Canton, SD
Lewis Family Drug: Chamberlain - Chamberlain, SD
Lewis Family Drug: De Smet - De Smet, SD
Lewis Family Drug: Dell Rapids - Dell Rapids, SD
Lewis Family Drug: Flandreau - Flandreau, SD
Lewis Drug: Huron - Huron, SD
Lewis Family Drug: Lake Preston - Lake Preston, SD
Lewis Family Drug: Lennox - Lennox, SD
Lewis Drug: Madison - Madison, SD
Lewis Family Drug: Milbank - Milbank, SD
Lewis Family Drug: Mitchell - Mitchell, SD
Lewis Family Drug: Mitchell County Fair - Mitchell, SD
Lewis Drug: 10th & Cliff Ave. Sioux Falls, SD - Sioux Falls, SD
Lewis Drug: 12th & Kiwanis Ave. Sioux Falls, SD - Sioux Falls, SD
Lewis Drug: 26th & Sycamore Ave. Sioux Falls, SD - Sioux Falls, SD
Lewis Drug: 41st & Marion Road Sioux Falls, SD - Sioux Falls, SD
Lewis Drug: 41st & Minnesota Ave. Sioux Falls, SD - Sioux Falls, SD
Lewis Drug: 69th & Louise Ave. Sioux Falls, SD - Sioux Falls, SD
Lewis Rx: Medical Building 2 - Sioux Falls, SD
Lewis Rx: Sanford Clinic - Sioux Falls, SD
Long Term Care: Sioux Falls - Sioux Falls, SD
Lewis Drug: Tea - Tea, SD
Lewis Family Drug: Viborg - Viborg, SD
Lewis Family Drug: Wessington Springs - Wessington Springs, SD
Lewis Family Drug: Wilmot - Wilmot, SD
umsllc... Thanks, but
Thanks for the link, but that company has a FDA 510k cleared brachytherapy product. Is it II or III.
I was referring to another company (Isor**) that already has successfully used theirs and was wondering if theirs was II or III.
Class II vs Class III
ADMD had the option to apply for class III status or class II status and chose II because it is cheaper and faster.(according to a PR they issued last year.)
A powered wheel chair sounds non invasive to me vs their product.
Why waste time going for II when III could be obtained too. If II is denied then they have to start all over again.
What classification has been obtained by the competition (IS*) already using their FDA approved brachytherapy?
Just curious.
Newark is in Essex County
NRTI headquarters is in Essex County, one of the three counties in NJ to offer Medical MJ dispesaries.
Capt...
You are correct, but I'm just saying there is a broader market place available when they want to take advantage of it
Medical Marijuana dispensaries, by state
I'm sure others have seen such a listing, but I post it to let everyone know that once the Nulief is actually up and running, there will be a very broad market place, to include the state of New Jersey where there are 3 dispensaries open now in Essix, Hudson and Atlantic counties. Anyone know which county NRTI headquarters is located?
I think we have a great future ahead.
Thanks CN for all your research.
Directory of Marijuana Dispensaries
Find a medical marijuana dispensary or cannabis club in your area. Our medical marijuana dispensaries include listings in all states where medical marijuana is legal in the U.S., including the District of Columbia.
Choose A State
Arizona Marijuana Dispensaries
California Marijuana Dispensaries
Colorado Marijuana Dispensaries
Florida Marijuana Dispensaries
Georgia Marijuana Dispensaries
Hawaii Marijuana Dispensaries
Illinois Marijuana Dispensaries
Indiana Marijuana Dispensaries
Iowa Marijuana Dispensaries
Kentucky Marijuana Dispensaries
Maine Marijuana Dispensaries
Massachusetts Marijuana Dispensaries
Michigan Marijuana Dispensaries
Mississippi Marijuana Dispensaries
Montana Marijuana Dispensaries
Nevada Marijuana Dispensaries
New Jersey Marijuana Dispensaries
New Mexico Marijuana Dispensaries
New York Marijuana Dispensaries
North Carolina Marijuana Dispensaries
Ohio Marijuana Dispensaries
Oregon Marijuana Dispensaries
Rhode Island Marijuana Dispensaries
Utah Marijuana Dispensaries
Virginia Marijuana Dispensaries
Washington Marijuana Dispensaries
competing product priced at 30 capsules $130.00
discounted if signed up for monthly auto purchase
Also found that they sell in any of the medical marijuana eligble states and take orders on line
Dixie Botanicals
Capsules-Leaf
Dixie Botanicals Hemp Oil Supplement 30 Capsules
Hemp Oil Supplement Carefully selected and extracted using a process designed to preserve its naturally-occurring constituents, Dixie Botanicals offers micro encapsulated hemp oil support to promote overall wellness.
Qty
Cost
$130.00 ea.
Join the Compassionate Care Program and Save 20%
When you join the Dixie Botanicals Compassionate Care Club you receive your Dixie Botanicals Hemp Oil Supplement products each month and save 20%. You get the convenience of regularly monthly shipments and receive significant savings.
Qty
Cost
$104.00 ea.
Saturdays presentation available on the company website
Gynecological Cancer Treatment
Gynecologic Treatment Using Cesium-131 Provides the Following Advantages: Gynecologic Treatment
Deliver the dose where you want. When it’s needed.
Cesium-I3I has delivered 90% of the intended dose 33 days post implant, compared to 32% of the I-125 dose.
Cesium-I3I has delivered 99.8% of the dose at 90 days, when the sutures/mesh have most likely dissolved, compared to 65% for I-125.
Once the carrier material has dissolved, the seeds are free to migrate and stop contributing to the prescription dose plan.
Cesium-I3I delivers uniform and symmetrical radiation penetration for a homogeneous cervical implant.
Dr. Feddock’s Gynecologic Cancer Treatment Presentaion Part 1 03/28/2015.
Dr. Feddock’s Gynecologic Cancer Treatment Presentaion Part 2.
Dr. Feddock’s Gynecologic Cancer Treatment Presentaion Part 3.
Dr. Feddock’s Gynecologic Cancer Treatment Presentaion Part 4.
Anybody hear how the Saturday conference went?
Gynecologic Cancers Successfully Treated Using IsoRay's Cesium-131 Will Be Presented by Dr. Jonathan Feddock Saturday Night While at the Society of Gynecologic Oncology Convention (SGO)Marketwired(Tue, Mar 24)
What is the equivalent in pain medications?
Each capsule is 25 mg of CBD... How many Alleve or IBprofen is that equivalent to?
How quickly does it take for a capsule to begin acting and how long is pain relief expected to last? I know each person taking it would be different but approximately.
How many capsules can be taken in 24 hour period.
TIA
Do you think the medical doctors from CNN and FOX will be there?
If I recall, Gupta from CNN did a few segments on TV about medical marijuana.. Hope he will be there.
Inergetics Introduces Nulief(TM), The First Branded Cannabinoid (CBD)-Based Nutritional Supplement
10:00 am ET March 26, 2015 (PR Newswire) Print
Inergetics,Inc. (OTCBB: NRTI), a world-class developer of NSF(R) Certified nutritional and consumer health products, announced today the launch of Nulief(TM), a branded nutritional supplement offering the holistic benefits associated with Cannabidiol (CBD).
The official launch of Nulief will take place this evening at Chef David Bouley's Bouley Botanical in New York City and will feature introductions by Inergetics' management regarding this historic event.
Nulief is the first nutraceutical in a line of products being developed by Inergetics' new Whole Products(R) division to offer consumers the convenient benefits of non-psychoactive CBD. CBD has emerged as a key element to help with proper functioning of the human endocannabinoid system (ECS) that assists the body to maintain stable internal conditions necessary to help protect it.
"Nulief is the next generation holistic medicine that will deliver therapy to those in need," said Mike James, CEO of Inergetics. "We are extremely proud to provide a new alternative without the harmful side effects and addictive attributes of synthetic opiates. The CBD in Nulief can help people who are experiencing discomfort caused by a range of conditions without the 'high' associated with THC found in traditional medicinal marijuana products. Nulief is a nutraceutical that takes Inergetics one step closer to realizing our vision of bringing a suite of farm to formula products to market. We are committed to expanding the Nulief brand into a portfolio of breakthrough supplements that are available in mainstream retail outlets."
Inergetics and Terra Tech developed Nulief under the insightful guidance and extensive expertise of the Scientific/Medical Advisory Board the companies convened in early 2014.
Initial Nulief Availability in Dispensaries
Nulief will be available in the coming weeks at Medical Marijuana Dispensaries associated with Terra Tech.
Chief Marketing Officer Jim Kras added, "Nulief is intended to offer convenient and affordable CBD to consumers, empowering them to take back control of their lives and restore their sense of hope and optimism. Making Nulief available to dispensary customers is our initial step toward bringing an accessible CBD-based line to the entire U.S. market through a range of retail partners. Inergetics has a proven ability to bring health and wellness products to the mass retail market. We are uniquely positioned to apply our distribution and marketing expertise to Nulief and deliver the next generation of holistic medicine. We are confident that Nulief will be a transformational dietary supplement brand for consumers as well as for retailers looking to offer an OTC solution from a proven world-class partner."
Expanding the Nulief Brand
Inergetics' new Whole Products division is developing other CBD-related products in the Nulief line, including one that combines CBD with important cannabinoids from other sources.
To provide information about Nulief to consumers, media and the investment community, Inergetics today launched a new website, www.nuliefcbd.com. In the coming weeks Inergetics will post to the website a video recorded at its Nulief launch event on March 26. In addition, the company will post updated information about Nulief to @NuliefCBD on Twitter and Nulief on Facebook.
Inergetics Media ContactKARV CommunicationsJonathan Leibowitz(212) 333-0273Inergetics@KARVCommunications.com
About Inergetics, Inc.Inergetics' portfolio of brands includes: Martha Stewart(TM) Essentials, a complete line of NSF(R) Certified, whole-food-based supplements created specifically for women; Surgex(R) Sports Nutrition, the preferred nutritional supplement of Army Sports; Bikini Ready(R), a leader in active lifestyle solutions; SlimTrim, the affordable, premium value diet brand; OmEssentials(R), a line of scientifically advanced nutritional supplements designed to further the health and wellness of yoga practitioners and active individuals; and Nulief(TM), a line of Cannabidiol (CBD)-based nutritional supplements. Inergetics' brands are available domestically and internationally at over 20,000 premier locations including Akins, Bed Bath & Beyond, Bi-Lo, Cardinal Health, Drug Emporium, Fruth Pharmacy, H-E-B, Harmon, Harris Teeter, Harveys, Ingles, Lewis Drugs, Meijer, Navarro Pharmacies, Price Chopper, PriceSmart, ShopRite/Wakefern, Walgreens, Whole Foods and Winn-Dixie as well as leading e-tailers such as Amazon, Bodybuilding.com, Bulu Box, CVS.com, Drugstore.com, iHerb, LuckyVitamin.com, Swanson, Vitacost, and Zulily.
To learn more about Inergetics, visit www.inergetics.com, and the Inergetics brands' websites at: www.marthastewartessentials.com, www.surgexsports.com, www.surgexsportsblitz.com, www.slimtrim1.com, www.slimtrim.net, www.bikinireadylifestyle.com, www.kahunasands.com, www.omessentials.com, and www.nuliefcbd.com.
NEWS today....Gynecologic Cancers Successfully Treated
Gynecologic Cancers Successfully Treated Using IsoRay's Cesium-131 Will Be Presented by Dr. Jonathan Feddock Saturday Night While at the Society of Gynecologic Oncology Convention (SGO)
8:02 am ET March 24, 2015 (Market Wire) Print
IsoRay Inc. (NYSE MKT: ISR) (www.isoray.com), a medical technology company and innovator in seed brachytherapy and medical radioisotope applications, today announced it will host a dinner presentation on March 28 by Dr. Jonathan Feddock describing the use, procedure and outstanding results in treating gynecologic cancers utilizing Cesium-131. IsoRay will have booth #516 at the 2015 Annual Meeting of the Society of Gynecologic Oncology (SGO). The annual meeting will take place March 28-31, 2015 at the Chicago Hilton in Chicago, Illinois.
According to IsoRay CEO Dwight Babcock, "With the recently published and peer-reviewed results for gynecologic cancer, we are seeing a growing level of interest by gynecologic oncologists due to the significant results being achieved using Cesium-131. Cesium-131's reported success in treating primary as well as recurrent gynecologic cancers that have not responded to other treatments continues to get the attention of physicians who need new treatment options."
IsoRay is very pleased to have Dr. Feddock, an industry leader who practices at University of Kentucky HealthCare, discuss the success, methods and new approaches being implemented in brachytherapy.
Mr. Babcock added, "The medical community is continually being shown the unique ability of IsoRay' s Cesium-131 (Cs-131) seeds, seed sutured, seeded mesh and GliaSite(R) system for the treatment of a wide array of cancers throughout the body. Medical thought leaders recognize the need for a new powerful weapon in the battle against cancer and we believe Cesium-131 is that solution. Our products offer an important advance over previous brain, head and neck, lung, prostate, abdominal wall and gynecological cancer treatments. We are extremely excited that published studies, posters and abstracts continue to be released showing positive results realized in treating metastasized brain cancers, gynecological cancers, lung cancer and prostate cancer using Cs-131 or GliaSite(R)."
IsoRay's Cesium-131 sutured seeds, stranded mesh and the GliaSite(R) radiation therapy system each give physicians the ability to directly place a specified dosage of radiation in areas where cancer is most likely to remain after tumor removal. The ability to precisely place a specified dose of radiation means there is less likelihood for damage to occur to healthy tissue as well as critical structures compared to other alternative treatments. IsoRay's cancer fighting products reduce the ability of the tumor to recur, which means important benefits for patients in longevity as well as quality of life.
IsoRay is the exclusive manufacturer of Cesium-131. Cesium-131 is the first new isotope to be available in seed form for brachytherapy in approximately 20 years. Cesium-131 allows for the precise treatment of many different cancers because of its unrivaled blend of high energy and its 9.7 day half-life (its unequaled speed in giving off therapeutic radiation).
In addition to its CMS codes, Cesium-131 is FDA-cleared and holds a CE mark for international sales in seed form for the treatment of brain cancer, prostate cancer, lung cancer, ocular melanoma cancer, colorectal cancer, gynecologic cancer, head and neck cancer and other cancers throughout the body. The treatment can be deployed using several delivery methods including single seed applicators, implantable strands and seed sutured mesh, and several new implantable devices. IsoRay also distributes the GliaSite(R) radiation therapy system, used to treat brain cancers.
About IsoRay IsoRay, Inc., through its subsidiary, IsoRay Medical, Inc. is the sole producer of Cesium-131 brachytherapy seeds, which are expanding brachytherapy options throughout the body. Learn more about this innovative Richland, Washington company and explore the many benefits and uses of GliaSite(R) and Cesium-131 by visiting www.isoray.com. Join us on Facebook/Isoray. Follow us on Twitter @Isoray.
Safe Harbor Statement Statements in this news release about IsoRay's future expectations, including: the advantages of our products and their delivery systems, future demand for IsoRay's existing and planned products, whether IsoRay will be able to continue to expand its base beyond prostate cancer, whether the use of our products will increase or continue, whether additional studies will be published or presented with favorable outcomes from treatment with our products, whether we will continue to receive support from industry leaders, whether awareness of our products in the medical community will continue or increase, whether future studies of treatment of various cancers using our products will have favorable results, whether awareness and adoption of our products by gynecologic oncologists will continue or grow, and all other statements in this release, other than historical facts, are "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995 ("PSLRA"). This statement is included for the express purpose of availing IsoRay, Inc. of the protections of the safe harbor provisions of the PSLRA. It is important to note that actual results and ultimate corporate actions could differ materially from those in such forward-looking statements based on such factors as physician acceptance, training and use of IsoRay's products, changing levels of demand for IsoRay's current and proposed future products, IsoRay's ability to reduce or maintain expenses while increasing sales, patient results achieved using our products in both the short and long term, success of future research and development activities, patient results achieved when Cesium-131 is used for the treatment of cancers and malignant diseases beyond prostate cancer, IsoRay's ability to successfully manufacture, market and sell its products, IsoRay's ability to manufacture its products in sufficient quantities to meet demand within required delivery time periods while meeting its quality control standards, the success of our sales and marketing efforts, IsoRay's ability to enforce its intellectual property rights, changes in reimbursement rates, changes in laws and regulations applicable to our products, whether additional studies and protocols are released and support the conclusions of past studies and protocols, whether ongoing patient results with our products are favorable and in line with the conclusions of clinical studies and initial patient results, whether we, our distributors and our customers will successfully obtain and maintain all required regulatory approvals and licenses to market, sell and use our products in their various forms, continued compliance with ISO standards as audited by BSI, and other risks detailed from time to time in IsoRay's reports filed with the SEC.
Contact:
IsoRay Medical
(509) 375-1202
Info@Isoray.com
Or
Worldwide Financial
Info@wwfinancial.com
(954) 360-9998
SOURCE: IsoRay, Inc.